How Vein Finders Improve First-Stick Success: The Case for Adoption

If you’re a nurse, clinical educator, or vascular access specialist, you know what it takes to make the case for your organization to invest in healthcare technology: clear clinical value for patients, supplier vetting for procurement, ROI for finance, IT engagement for implementation, and a leadership stamp of approval.

This article pulls together in one place the clinical and operational evidence for vein finder technology adoption. The goal is to give you a defensible, evidence-backed case to take to your manager, your purchasing committee, or your director of nursing. Each claim in this article links to its original source so you can cite it directly.

The clinical problem vein finder technology addresses

Peripheral IV access is one of the most common procedures performed in healthcare, and one of the most likely to fail on the first attempt. The published evidence on first-attempt failure rates varies by population and setting, but the rates are consistently high enough that the negative consequences are clinically meaningful.

Failed attempts have direct consequences for patients. Pain increases. Anxiety builds. For pediatric patients, multiple sticks can be traumatic enough to affect the child’s relationship with future medical care. For oncology patients, dialysis patients, and others requiring repeated access, accumulated failed attempts compromise the vasculature itself, making subsequent access progressively more difficult.

There are operational consequences as well. Failed sticks consume supplies and nursing time. Patients wait longer for treatment. Difficult access cases often escalate to specialty IV teams, or nursing or physician involvement, which delays care and uses resources that could be deployed elsewhere.

The clinicians performing this work feel it. Failed sticks erode confidence, contribute to burnout in patient-facing roles, and create avoidable conflict in care environments where staff are already stretched.

Vein visualization technology was developed to positively address exactly this problem. The question for any facility is not whether the technology works but how best to utilize it for their patient population and operational context.

What the evidence shows on first-stick success

One of the strongest pieces of published evidence for vein visualization comes from studies in populations with anticipated difficult access.

A randomized controlled trial of pediatric patients aged 0 to 3 years by Demir and Inal, published in Pediatric Emergency Care, studied the effect of vein visualization on peripheral venous catheter placement. The study documented improvements in success rate, number of attempts, procedure duration, and pain levels when vein visualization was used compared to standard technique. A separate analysis by the same authors, also published in Pediatric Emergency Care, reported a first-stick success rate of 91.7% when vein visualization was used compared to 47.4% with the standard method.

The patient populations where the evidence is strongest include pediatric patients (especially those under three years and those with difficult access), patients with darker skin tones where visual assessment is less reliable, patients with edema or obesity where palpation is compromised, oncology and infusion patients whose vasculature has been damaged by repeated access, and dialysis patients whose access points are often limited.

NextVein maintains a clinical evidence library with citations to the published research, which you can reference directly when building your internal case.

The patient experience case

First-stick success matters operationally. For clinical advocates building an investment case, the positive patient experience outcome often resonates strongly with leadership.

Reduced pain is documented in the published literature. Patient satisfaction with the procedure tends to improve when fewer attempts are required, which has implications beyond comfort: HCAHPS scores and other patient experience metrics influence reimbursement and reputation at the facility level. Magnet Recognition, a designation from the American Nurses Credentialing Center held by fewer than 10% of US hospitals, is partially evaluated on patient satisfaction and nursing-sensitive outcomes. Hospitals pursuing or maintaining Magnet status have measurable reasons to invest in technology that improves the procedures patients remember.

For pediatric facilities, the case is particularly strong. Multiple failed IV attempts in young children are not just painful in the moment. They affect compliance with future medical care, family confidence in the facility, and staff morale around procedures that should be routine. A device that meaningfully improves first-stick success in this population addresses all of these concerns simultaneously.

For oncology and infusion centers, the case is different but equally compelling. These patients face repeated access throughout their treatment course. Each failed attempt damages remaining vasculature, making future access progressively harder. A technology that improves first-stick success in this population is not only addressing today’s procedure but protecting tomorrow’s access.

For aesthetic and cosmetic settings, vein visualization addresses a high-priority concern: vein avoidance. The face contains a complex network of superficial veins, many invisible to the naked eye. According to the FDA, the most serious risk associated with dermal fillers is accidental injection into a blood vessel, which can cause skin necrosis (death of tissue), stroke, or blindness. While the chances of this happening are low, the resulting complications can be serious and may be permanent. Vein visualization gives injectors a real-time map of the vessels they need to avoid.

The operational and financial case

For discussions with procurement or finance departments, prepare analyses about cost and return on investment. The published data supports several lines of justification.

Failed IV attempts have direct material and labor costs. Each failed stick consumes catheter supplies, dressings, and nursing time. Across a typical facility’s volume, this adds up. A 200-bed hospital performing thousands of IV procedures per month accumulates real waste from failed attempts that could be addressed with better first-stick success.

When peripheral access fails repeatedly, cases escalate to central IV teams using ultrasound-guided placement, PICC lines, or central venous catheters. Each of these is more expensive, takes longer, and carries higher complication risk than achieving a successful first peripheral stick.

The CLABSI argument is of the highest leverage for inpatient settings. According to published data on NCBI Bookshelf, central line-associated bloodstream infections (CLABSIs) account for approximately $46,000 per case in cost burden. CLABSIs are also classified by CMS as a “never event,” meaning reimbursement is denied. Any technology that supports reduced unnecessary central line placement by improving peripheral access success has a clear financial case in inpatient settings.

The patient experience itself has documented financial implications. A study by Richter and Muhlestein published in Health Care Management Review found that a positive patient experience is associated with increased profitability and a negative patient experience is even more strongly associated with decreased profitability. The authors note that improvements in training, technology, and staffing can be justified as a way to improve not only quality but profitability as well. This is a useful reference when finance reviewers ask whether patient experience investments produce measurable returns.

Staff retention is harder to quantify but worth considering. Repeated failed sticks contribute to nurse frustration in patient-facing roles, particularly in pediatrics, oncology, and emergency settings. Technology that supports clinician success in difficult procedures is part of the broader investment in staff experience and retention.

NextVein supports the financial case in two specific ways. First, our pricing is positioned to make adoption realistic for facilities that have previously found vein visualization technology cost-prohibitive. Second, our Total Protection Plan bundles the warranty, battery coverage, forward-swap replacement, and US-based service into a single offering, which makes the total cost of ownership predictable rather than open-ended.

Making the investment case

If you’re advocating internally for vein finder adoption, here is a framework for structuring your proposal.

Start with the clinical problem at your facility specifically. Generic arguments about IV access are less persuasive than specific arguments about your patients. Pull data from your own facility if you can: failed IV rates in your difficult-access populations, time spent on difficult sticks, escalations to specialty teams. If facility-level data is not available, use department-level estimates or staff observations.

Cite the evidence selectively but credibly. The Demir and Inal studies and the Richter and Muhlestein patient experience study are strong, defensible pieces of published evidence. You do not need to cite every study to make the case. Two or three strong references, properly attributed, are more persuasive than a long bibliography.

Translate the clinical evidence into operational language. Procurement and finance respond to dollar figures, time savings, and risk reduction. The clinical data on first-stick success becomes “fewer failed attempts at material and labor cost X.” The escalation data becomes “fewer unnecessary central line placements at average cost Y.” The pain data becomes “improved HCAHPS scores in the patient experience metrics we already track.”

Consider a structured evaluation rather than a direct purchase. Some facilities are more comfortable approving an evaluation period than a purchase, and most vendors should support one. NextVein offers a no-cost in-facility evaluation system with a standard 7-day evaluation period so your facility can use the device with real patients before any purchase commitment. Coming to leadership with “I’d like to do a weeklong evaluation and report back” is an easier ask than “I’d like to purchase this.”

Anticipate the cost objection. Total cost of ownership matters, not just purchase price. A device with service and warranty included often costs less over three years than a less-expensive device requiring paid extended coverage. Bring the total picture, not just the sticker price.

Identify the right approval path. In some facilities, nursing leadership can approve evaluation devices directly. In others, you’ll need to go through procurement, supply chain, or capital budget review. Understanding the right path before you start advocating saves time.

NextVein professionals can assist you in preparation of business cases, using field experience and financial frameworks.

Where NextVein fits

NextVein was founded specifically to make hospital-grade vein visualization accessible to facilities that could not justify the cost of alternatives on the market. Our V800NV handheld vein finder delivers the core clinical functionality documented in the studies referenced above at a price point designed to make adoption realistic across hospital settings, ambulatory surgery centers, infusion centers, med spas, and other clinical environments.

A few details worth knowing as you build your internal case:

The V800NV is a non-contact, near-infrared LED projection device. It requires no calibration, no consumables, and no setup time. Power on, hold above the patient’s arm, and see the projected vein map directly on the skin. It converts from handheld to hands-free use with a wheeled stand for procedures requiring both clinician hands.

NextVein is US-based, with a US-based customer support team and service infrastructure. When devices need service, the response time is measured in days, not weeks. The Total Protection Plan includes forward-swap replacement, so your team is never without a working device while one is in service.

The device is FDA Class 1 510(k) exempt in the US and Class 1 in the EU. Specific regulatory information is available on our regulatory information page.

For clinical reference materials supporting your internal proposal, our clinical evidence library summarizes the published research on vein visualization with citations to the original sources. If you’d like to include NextVein in your facility’s evaluation, you can request a no-cost evaluation system for in-facility use. For specific pricing and quote information, request a price quote directly.

Closing

The clinical case for vein visualization is well-supported by published evidence. The operational case follows directly from the clinical findings: fewer failed attempts, fewer escalations, lower costs, better patient experience. The pathway to adoption at most facilities is not whether the technology works but how the investment is justified in the specific setting and how to make that case internally.

The role of the clinical advocate in this process is decisive. Leadership rarely initiates conversations about technology adoption on their own. The cases that move forward are usually the ones where a nurse, clinical educator, or vascular access specialist takes responsibility for assembling the evidence, identifying the right approver, and making the proposal. The evidence to support those conversations exists. This article aims to make that evidence easier to use.

If you’re ready to evaluate vein visualization technology at your facility, NextVein offers both in-facility evaluation systems and direct price quotes. Whichever vendor you ultimately choose, the work of advocating for this technology in your facility is worth doing.